{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:34:58Z","timestamp":1792607698293,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["nanomedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.nano.2014.03.015","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T06:01:21Z","timestamp":1396418481000},"page":"1353-1363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD"],"prefix":"10.1016","volume":"10","author":[{"given":"Michal","family":"Mizrahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Friedman-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liraz","family":"Larush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Frid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orli","family":"Binyamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvir","family":"Dori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Fainstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Ovadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamir","family":"Ben-Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Magdassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Gabizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.nano.2014.03.015_bb0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/14789450.4.5.591","article-title":"New access to Alzheimer's and other neurodegenerative diseases","volume":"4","author":"Hamacher","year":"2007","journal-title":"Expert Rev Proteomics"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrd3050","article-title":"Protein aggregation diseases: pathogenicity and therapeutic perspectives","volume":"9","author":"Aguzzi","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.nano.2014.03.015_bb0015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/187152709789541998","article-title":"Cross currents in protein misfolding disorders: interactions and therapy","volume":"8","author":"Morales","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"4542","key":"10.1016\/j.nano.2014.03.015_bb0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.6801762","article-title":"Novel proteinaceous infectious particles cause scrapie","volume":"216","author":"Prusiner","year":"1982","journal-title":"Science"},{"issue":"31","key":"10.1016\/j.nano.2014.03.015_bb0025","doi-asserted-by":"crossref","first-page":"12571","DOI":"10.1073\/pnas.0906759106","article-title":"Is Parkinson's disease a prion disorder?","volume":"106","author":"Olanow","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2014.03.015_bb0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev-genet-110711-155524","article-title":"Biology and genetics of prions causing neurodegeneration","volume":"47","author":"Prusiner","year":"2013","journal-title":"Annu Rev Genet"},{"issue":"1","key":"10.1016\/j.nano.2014.03.015_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4161\/pri.23061","article-title":"Prions, prionoids and pathogenic proteins in Alzheimer disease","volume":"7","author":"Ashe","year":"2013","journal-title":"Prion"},{"issue":"9","key":"10.1016\/j.nano.2014.03.015_bb0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0047-6374(01)00249-4","article-title":"Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins","volume":"122","author":"Butterfield","year":"2001","journal-title":"Mech Ageing Dev"},{"issue":"6","key":"10.1016\/j.nano.2014.03.015_bb0045","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2174\/138161206775474297","article-title":"Antioxidants as a potential therapy against age-related neurodegenerative diseases: amyloid beta toxicity and Alzheimer's disease","volume":"12","author":"Hajieva","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.nano.2014.03.015_bb0050","first-page":"421","article-title":"Punicic acid is an omega-5 fatty acid capable of inhibiting breast cancer proliferation","volume":"36","author":"Grossmann","year":"2010","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.nano.2014.03.015_bb0055","doi-asserted-by":"crossref","first-page":"e1000977","DOI":"10.1371\/journal.ppat.1000977","article-title":"Oxidation of helix-3 methionines precedes the formation of PK resistant PrP","volume":"6","author":"Canello","year":"2010","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.nano.2014.03.015_bb0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr Neuropharmacol"},{"issue":"Pt 7","key":"10.1016\/j.nano.2014.03.015_bb0065","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awr128","article-title":"Oxidative damage in multiple sclerosis lesions","volume":"134","author":"Haider","year":"2011","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.nano.2014.03.015_bb0070","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1089\/ars.2011.4406","article-title":"4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies","volume":"17","author":"Perluigi","year":"2012","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.nano.2014.03.015_bb0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/ars.2009.2668","article-title":"Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities","volume":"12","author":"Adibhatla","year":"2010","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"10.1016\/j.nano.2014.03.015_bb0080","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.freeradbiomed.2011.06.027","article-title":"Lipid peroxidation and neurodegenerative disease","volume":"51","author":"Reed","year":"2011","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0085","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3233\/JAD-2010-100405","article-title":"Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein","volume":"21","author":"Singh","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"1500","key":"10.1016\/j.nano.2014.03.015_bb0090","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1098\/rstb.2008.2273","article-title":"Progress in the pathogenesis and genetics of Parkinson's disease","volume":"363","author":"Mizuno","year":"2008","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"6","key":"10.1016\/j.nano.2014.03.015_bb0095","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/mds.23685","article-title":"Milestones in huntington disease","volume":"26","author":"Shoulson","year":"2011","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.nano.2014.03.015_bb0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/cr.2011.116","article-title":"APP physiological and pathophysiological functions: insights from animal models","volume":"22","author":"Guo","year":"2012","journal-title":"Cell Res"},{"key":"10.1016\/j.nano.2014.03.015_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00401-010-0713-y","article-title":"Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy","volume":"121","author":"Kovacs","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"16","key":"10.1016\/j.nano.2014.03.015_bb0110","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199104183241604","article-title":"Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease","volume":"324","author":"Hsiao","year":"1991","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.nano.2014.03.015_bb0115","doi-asserted-by":"crossref","first-page":"e1002350","DOI":"10.1371\/journal.ppat.1002350","article-title":"Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease","volume":"7","author":"Friedman-Levi","year":"2011","journal-title":"PLoS Pathog"},{"issue":"4","key":"10.1016\/j.nano.2014.03.015_bb0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00005792-199707000-00001","article-title":"Familial Creutzfeldt-Jakob disease. Codon 200 prion disease in Libyan Jews","volume":"76","author":"Meiner","year":"1997","journal-title":"Medicine (Baltimore)"},{"issue":"15","key":"10.1016\/j.nano.2014.03.015_bb0125","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1212\/01.wnl.0000308955.25760.c2","article-title":"Systematic review of therapeutic interventions in human prion disease","volume":"70","author":"Stewart","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nano.2014.03.015_bb0130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1474-4422(09)70050-X","article-title":"Clinical trials for prion disease: difficult challenges, but hope for the future","volume":"8","author":"Geschwind","year":"2009","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.nano.2014.03.015_bb0135","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","article-title":"Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study","volume":"62","author":"Otto","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nano.2014.03.015_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Haik","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.nano.2014.03.015_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-8741(98)00222-0","article-title":"Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids","volume":"66","author":"Schubert","year":"1999","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.nano.2014.03.015_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-0-12-024911-4.50010-6","article-title":"Uptake and transport of fatty acids into the brain and the role of the blood\u2013brain barrier system","volume":"11","author":"Dhopeshwarkar","year":"1973","journal-title":"Adv Lipid Res"},{"issue":"2","key":"10.1016\/j.nano.2014.03.015_bb0155","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1471-4159.1988.tb02958.x","article-title":"Fatty acid transport through the blood\u2013brain barrier","volume":"50","author":"Spector","year":"1988","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.nano.2014.03.015_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00966806","article-title":"Linoleic acid passage through the blood\u2013brain barrier and a possible effect of age","volume":"19","author":"Avellini","year":"1994","journal-title":"Neurochem Res"},{"issue":"10","key":"10.1016\/j.nano.2014.03.015_bb0165","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/mnfr.200800520","article-title":"Incorporation and metabolism of punicic acid in healthy young humans","volume":"53","author":"Yuan","year":"2009","journal-title":"Mol Nutr Food Res"},{"issue":"2-3","key":"10.1016\/j.nano.2014.03.015_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cbi.2011.02.030","article-title":"Antioxidant effect of vegetable oils containing conjugated linolenic acid isomers against induced tissue lipid peroxidation and inflammation in rat model","volume":"190","author":"Saha","year":"2011","journal-title":"Chem Biol Interact"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0175","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.bbagen.2012.12.012","article-title":"Incorporation of beta-sitosterol into the membrane increases resistance to oxidative stress and lipid peroxidation via estrogen receptor-mediated PI3K\/GSK3beta signaling","volume":"1830","author":"Shi","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"25","key":"10.1016\/j.nano.2014.03.015_bb0180","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1021\/jf072741q","article-title":"Pomegranate oil analysis with emphasis on MALDI-TOF\/MS triacylglycerol fingerprinting","volume":"55","author":"Kaufman","year":"2007","journal-title":"J Agric Food Chem"},{"issue":"7","key":"10.1016\/j.nano.2014.03.015_bb0185","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/09687688.2010.516276","article-title":"Multifunctionality of lipid-core micelles for drug delivery and tumour targeting","volume":"27","author":"Sawant","year":"2010","journal-title":"Mol Membr Biol"},{"issue":"11","key":"10.1016\/j.nano.2014.03.015_bb0190","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.2967\/jnumed.113.121657","article-title":"Synthetic lipid nanoparticles targeting steroid organs","volume":"54","author":"Merian","year":"2013","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0195","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.nano.2008.11.004","article-title":"Formation of simvastatin nanoparticles from microemulsion","volume":"5","author":"Margulis-Goshen","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2014.03.015_bb0200","first-page":"451","article-title":"Bioavailability of nanoemulsified conjugated linoleic acid for an antiobesity effect","volume":"8","author":"Kim","year":"2013","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"10.1016\/j.nano.2014.03.015_bb0205","doi-asserted-by":"crossref","first-page":"e69583","DOI":"10.1371\/journal.pone.0069583","article-title":"PrPST, a soluble, protease resistant and truncated PrP form features in the pathogenesis of a genetic prion disease","volume":"8","author":"Friedman-Levi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2014.03.015_bb0210","first-page":"41","article-title":"Time associated decline in neurotrophic properties of neural stem cell grafts render them dependent on brain region-specific environmental support","volume":"49C","author":"Fainstein","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.nano.2014.03.015_bb0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jnutbio.2013.10.002","article-title":"Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals","volume":"25","author":"Wang","year":"2013","journal-title":"J Nutr Biochem"},{"issue":"12","key":"10.1016\/j.nano.2014.03.015_bb0220","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1212\/WNL.40.12.1820","article-title":"Inherited human prion diseases","volume":"40","author":"Hsiao","year":"1990","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nano.2014.03.015_bb0225","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/archneur.65.6.762","article-title":"Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin","volume":"65","author":"Haviv","year":"2008","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0230","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0092-8674(85)80082-9","article-title":"Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles","volume":"41","author":"Wiedenmann","year":"1985","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.nano.2014.03.015_bb0235","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1073\/pnas.83.10.3500","article-title":"Synaptophysin: a marker protein for neuroendocrine cells and neoplasms","volume":"83","author":"Wiedenmann","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.nano.2014.03.015_bb0240","first-page":"66","article-title":"Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia","volume":"4","author":"Zhan","year":"1993","journal-title":"Dementia"},{"issue":"1","key":"10.1016\/j.nano.2014.03.015_bb0245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1750-3639.1993.tb00728.x","article-title":"The role of synaptic proteins in the pathogenesis of disorders of the central nervous system","volume":"3","author":"Masliah","year":"1993","journal-title":"Brain Pathol"},{"key":"10.1016\/j.nano.2014.03.015_bb0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1749-6632.1993.tb23028.x","article-title":"Synaptic pathology of Alzheimer's disease","volume":"695","author":"Lassmann","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.nano.2014.03.015_bb0255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00001756-199301000-00017","article-title":"Synaptic degeneration is the primary neuropathological feature in prion disease: a preliminary study","volume":"4","author":"Clinton","year":"1993","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0260","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/14734220260418448","article-title":"Synaptic pathology and cell death in the cerebellum in Creutzfeldt-Jakob disease","volume":"1","author":"Ferrer","year":"2002","journal-title":"Cerebellum"},{"issue":"5","key":"10.1016\/j.nano.2014.03.015_bb0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1439-0450.2004.00755.x","article-title":"Neuropathological findings in brains of Bavarian cattle clinically suspected of bovine spongiform encephalopathy","volume":"51","author":"Miyashita","year":"2004","journal-title":"J Vet Med B Infect Dis Vet Public Health"},{"issue":"10","key":"10.1016\/j.nano.2014.03.015_bb0270","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1046\/j.1460-9568.2003.02662.x","article-title":"Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease","volume":"17","author":"Cunningham","year":"2003","journal-title":"Eur J Neurosci"},{"issue":"9","key":"10.1016\/j.nano.2014.03.015_bb0275","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archneur.58.9.1395","article-title":"Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease","volume":"58","author":"Price","year":"2001","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.nano.2014.03.015_bb0280","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1523\/JNEUROSCI.4608-03.2004","article-title":"Neural stem cell detection, characterization, and age-related changes in the subventricular zone of mice","volume":"24","author":"Maslov","year":"2004","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.nano.2014.03.015_bb0285","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/3305","article-title":"Neurogenesis in the adult human hippocampus","volume":"4","author":"Eriksson","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.nano.2014.03.015_bb0290","doi-asserted-by":"crossref","first-page":"260925","DOI":"10.1155\/2013\/260925","article-title":"Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches","volume":"2013","author":"Fuster-Matanzo","year":"2013","journal-title":"Mediators Inflamm"},{"issue":"1-4","key":"10.1016\/j.nano.2014.03.015_bb0295","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000335380","article-title":"Neuroinflammation and common mechanism in Alzheimer's disease and prion amyloidosis: amyloid-associated proteins, neuroinflammation and neurofibrillary degeneration","volume":"10","author":"Rozemuller","year":"2012","journal-title":"Neurodegener Dis"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0300","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/138920107780906531","article-title":"Bromodeoxyuridine and the detection of neurogenesis","volume":"8","author":"Kuhn","year":"2007","journal-title":"Curr Pharm Biotechnol"},{"issue":"12","key":"10.1016\/j.nano.2014.03.015_bb0305","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.neurobiolaging.2005.10.006","article-title":"Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease","volume":"27","author":"Freixes","year":"2006","journal-title":"Neurobiol Aging"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0310","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1172\/JCI118853","article-title":"Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma","volume":"98","author":"Palinski","year":"1996","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.nano.2014.03.015_bb0315","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.nbd.2011.12.020","article-title":"Copper is toxic to PrP-ablated mice and exacerbates disease in a mouse model of E200K genetic prion disease","volume":"45","author":"Canello","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.nano.2014.03.015_bb0320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.106.110866","article-title":"Protective effect of sulforaphane against dopaminergic cell death","volume":"321","author":"Han","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.nano.2014.03.015_bb0325","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00018-008-7452-4","article-title":"Curcumin: from ancient medicine to current clinical trials","volume":"65","author":"Hatcher","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.nano.2014.03.015_bb0330","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0024-3205(01)01438-2","article-title":"The green tea polyphenol (\u2212)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons","volume":"70","author":"Choi","year":"2001","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.nano.2014.03.015_bb0335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1124\/jpet.113.205799","article-title":"Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice","volume":"347","author":"Lu","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.nano.2014.03.015_bb0340","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbrc.2003.10.150","article-title":"Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis","volume":"312","author":"Schonberger","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.nano.2014.03.015_bb0345","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.nano.2014.03.015_bb0350","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4155\/tde.13.30","article-title":"Immunotherapeutic approaches in prion disease: progress, challenges and potential directions","volume":"4","author":"Brazier","year":"2013","journal-title":"Ther Deliv"},{"issue":"6848","key":"10.1016\/j.nano.2014.03.015_bb0355","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35089090","article-title":"Antibodies inhibit prion propagation and clear cell cultures of prion infectivity","volume":"412","author":"Peretz","year":"2001","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.nano.2014.03.015_bb0360","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/187152709789541934","article-title":"RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?","volume":"8","author":"White","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"17","key":"10.1016\/j.nano.2014.03.015_bb0365","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1073\/pnas.1303510110","article-title":"Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents","volume":"110","author":"Karapetyan","year":"2013","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963414001336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963414001336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:31:01Z","timestamp":1565310661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963414001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1549963414001336"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2014.03.015","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2014.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}